Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
Ryan Allway July 19th, 2022 Psychedelics, Top News Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure DENVER, July 19, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology... Read more
Doseology Expands into US Retail Market
Ryan Allway July 14th, 2022 Psychedelics, Top News VERNON, BC, July 14, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is excited to announce it has signed a Sales Management Agreement with Alternative Sales Management... Read more
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
Ryan Allway July 13th, 2022 News, Psychedelics, Top News FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”),... Read more
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
July 13, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a... Read more
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
Ryan Allway July 6th, 2022 Psychedelics, Top News VANCOUVER, BC, July 6, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has... Read more
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program – Ketamine-Assisted Therapy for Alcohol Use Disorder
Ryan Allway July 5th, 2022 Psychedelics, Top News Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and... Read more
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Ryan Allway June 27th, 2022 Psychedelics, Top News — Marks the first novel psilocybin analog to enter clinical development —— Patient recruitment to commence immediately —— Pharmacokinetic and safety data readout expected in Q4 2022 — TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company... Read more
PharmAla Biotech Registers Trademark for MDMA
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Tryp Therapeutics Appoints New Chief Operating Officer
Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments San Diego, California — (June 23, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused... Read more
Irwin Naturals Continues To Expand Clinic Footprint
Ryan Allway June 21st, 2022 News, Psychedelics, Top News LOS ANGELES, June 21, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) will add to its rapidly growing chain of psychedelic mental health centers, announcing today that it has signed a definitive agreement... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )